Last mentioned: Mar 23, 2026
JPM Q1 Earnings Report
JPMorgan Chase reports first-quarter financial results amidst regulatory and legal scrutiny.
FDA Orforglipron Decision
Expected regulatory ruling on Eli Lilly's oral GLP-1 candidate for weight loss.
Impurity Discovery
Lilly announces discovery of impurities in compounded samples and issues safety warnings.
Shortage Resolution
Expected timeframe for tirzepatide to be removed from FDA shortage list, ending legal compounding.
Impurity Warning
Lilly issues formal warning after testing reveals bacterial contamination in compounded samples.
Shortage Surge
Widespread shortages lead to a massive increase in compounding pharmacy production.
Initial Lawsuits
Lilly begins filing legal actions against medspas for trademark infringement.
Zepbound Approval
FDA approves Zepbound for chronic weight management.
Shortage Begins
FDA adds tirzepatide to the official drug shortage list, enabling compounding.
Mounjaro Approval
FDA approves Mounjaro for Type 2 diabetes treatment.
Investors are monitoring two critical mid-April deadlines: the FDA's decision on Eli Lilly's oral weight-loss drug, orforglipron, and JPMorgan Chase's first-quarter earnings report. These events serve as key indicators for the pharmaceutical sector's obesity market expansion and the banking sector's regulatory resilience.
Eli Lilly has issued a formal warning regarding the discovery of impurities in compounded versions of its popular weight-loss treatments. The pharmaceutical giant highlighted significant safety risks associated with these unapproved alternatives, which have proliferated during ongoing supply shortages.
Eli Lilly has issued a formal warning after discovering impurities in compounded versions of its blockbuster weight-loss medication. The pharmaceutical giant cautioned that these unapproved formulations pose significant health risks to patients seeking alternatives during supply shortages.
Eli Lilly and Veeva Systems emerge as dominant healthcare growth leaders for 2026, driven by the GLP-1 weight-loss revolution and cloud-based life sciences infrastructure. Meanwhile, SoundHound AI is positioning itself to disrupt medical administrative costs through generative voice AI and automated customer service solutions.
This page surfaces every story mentioning tirzepatide across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where tirzepatide was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |